logo

English
  • Svenska
  • About Us
    About Us
      • This is Calliditas
      • Vision and Strategy
      • Board of Directors
      • Management Team
      • Our History
      • Corporate Responsibility
        • Expanded Access Policy
      • Careers
  • Science
    Science
      • Our Pipeline
      • Nefecon (ex-US Markets)
      • Setanaxib – NOX Platform
      • Orphan drugs
  • Our Product
  • Governance
    Governance
      • Corporate Governance
      • Corporate Governance Reports
      • Corporate Structure
      • General Meeting
        • Annual general meeting 2022
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal Control and Risk Management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The Share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • SEC Filings
      • Press Releases
      • Financial Calendar
      • IR Calendar
      • Subscribe
      • Contacts
      • Investor FAQs
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Calliditas Media Kit
      • TARPEYO Media Kit (US audience only)
      • Subscribe
      • Contacts
  • Contact Us
    Contact Us
      • Offices
      • Partnerships and Inquires
      • Investor Relations
      • Media
      • Medical Inquiries
  • Svenska

Press Releases

Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

All press releases
  • Regulatory press releases
  • Non-regulatory press releases
2017
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2016
  • 2015
  • 2014
  • 2012
  • 2010
  • 2009
  • 2008
  • All years
Nov 20, 2017

Surrogate marker and design of Calliditas Therapeutics’ IgA nephropathy Phase 3 study agreed with the FDA

Nov 15, 2017

Pharmalink is renamed Calliditas Therapeutics

Aug 24, 2017

Thomas Eklund New Chairman of Pharmalink

Aug 15, 2017

Pharmalink strengthens its management team. Appoints new Chief Financial Officer and head of communications

Jul 4, 2017

Positive Phase 2b Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy presented at Leading Kidney Disease Conference

May 31, 2017

Positive Phase 2b Trial of Pharmalink’s Nefecon in IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference

May 18, 2017

Pharmalink AB announces the appointment of a new Chief Executive Officer

Mar 29, 2017

Positive results of Phase 2b Clinical Trial of Pharmalink’s Nefecon in Primary IgA Nephropathy published in The Lancet

  • Media
    • Press Releases
    • Calliditas in Media
    • Subscribe
    • Contacts

Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2022